DK3518933T4 - Fremgangsmåder til behandling af uterusfibromer og endometriose - Google Patents

Fremgangsmåder til behandling af uterusfibromer og endometriose Download PDF

Info

Publication number
DK3518933T4
DK3518933T4 DK17823018.1T DK17823018T DK3518933T4 DK 3518933 T4 DK3518933 T4 DK 3518933T4 DK 17823018 T DK17823018 T DK 17823018T DK 3518933 T4 DK3518933 T4 DK 3518933T4
Authority
DK
Denmark
Prior art keywords
endometriosis
methods
treating uterine
uterine fibromas
fibromas
Prior art date
Application number
DK17823018.1T
Other languages
Danish (da)
English (en)
Other versions
DK3518933T3 (da
Inventor
Jr Paul N Mudd
Susan Wollowitz
Mark Hibberd
Vijaykumar Reddy Rajasekhar
Lynn Seely
Mayukh Vasant Sukhatme
Masataka Tanimoto
Brendan Mark Johnson
Original Assignee
Takeda Pharmaceuticals Co
Sumitomo Pharma Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3518933(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co, Sumitomo Pharma Switzerland Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of DK3518933T3 publication Critical patent/DK3518933T3/da
Application granted granted Critical
Publication of DK3518933T4 publication Critical patent/DK3518933T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
DK17823018.1T 2016-09-30 2017-09-29 Fremgangsmåder til behandling af uterusfibromer og endometriose DK3518933T4 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402055P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (2)

Publication Number Publication Date
DK3518933T3 DK3518933T3 (da) 2022-05-30
DK3518933T4 true DK3518933T4 (da) 2025-04-22

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17823018.1T DK3518933T4 (da) 2016-09-30 2017-09-29 Fremgangsmåder til behandling af uterusfibromer og endometriose

Country Status (24)

Country Link
US (4) US11033551B2 (enExample)
EP (2) EP4094766B1 (enExample)
JP (1) JP7043503B2 (enExample)
CN (1) CN110312512B (enExample)
AU (2) AU2017336363B2 (enExample)
BR (1) BR112019006227A2 (enExample)
CA (1) CA3038879A1 (enExample)
CY (1) CY1125254T1 (enExample)
DK (1) DK3518933T4 (enExample)
ES (2) ES2912929T5 (enExample)
FI (1) FI3518933T4 (enExample)
HR (1) HRP20220708T4 (enExample)
HU (2) HUE072130T2 (enExample)
IL (2) IL300580B2 (enExample)
LT (1) LT3518933T (enExample)
MD (1) MD3518933T4 (enExample)
MX (1) MX2019003726A (enExample)
NZ (1) NZ752916A (enExample)
PL (2) PL3518933T5 (enExample)
PT (1) PT3518933T (enExample)
RS (1) RS63300B2 (enExample)
SI (1) SI3518933T2 (enExample)
SM (1) SMT202200254T1 (enExample)
WO (1) WO2018060501A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
ES3018358T3 (es) 2017-06-05 2025-05-16 Kissei Pharmaceutical Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
AU2018419533A1 (en) * 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
MA54058A (fr) * 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
JP2022543308A (ja) * 2019-08-08 2022-10-11 オブセヴァ エス．エー． エストロゲン依存性障害の治療のための組成物及び方法
CN115279769A (zh) * 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
IL295781A (en) * 2020-02-19 2022-10-01 Aspira Women’S Health Inc Preparations with improved specificity for the evaluation of endometriosis
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
AU2021278303A1 (en) * 2020-05-29 2023-02-09 Sumitomo Pharma Switzerland Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
WO2024102620A2 (en) * 2022-11-09 2024-05-16 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402055A (en) 1889-04-23 Water-motor
US492839A (en) 1893-03-07 Key for brake-shoes
US402150A (en) 1889-04-30 Broadcast seed-sower
US402034A (en) 1889-04-23 Dumping-wagon
US528409A (en) 1894-10-30 Denis ahern
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
AU2001234188A1 (en) 2000-02-29 2001-09-12 Takeda Chemical Industries Ltd. Processes for the production of thienopyrimidine derivatives
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
KR101074462B1 (ko) 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
KR101139148B1 (ko) 2003-07-07 2012-04-26 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀-방출 호르몬 수용체 길항제로서의피리미딘-2,4-디온 유도체
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
NZ566038A (en) 2005-07-22 2011-06-30 Takeda Pharmaceutical The use of thieno(2,3-d)pyrimidine-2,4-dione derivatives which are gonadotropin releasing hormone (GnRH) antagonists as premature ovulation preventive agent
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
HRP20190729T1 (hr) 2012-09-28 2019-06-14 Takeda Pharmaceutical Company Limited Metoda proizvodnje derivata tienopirimidina
EP2968566A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding and uterine fibroids
ES2988678T3 (es) 2015-02-26 2024-11-21 Takeda Pharmaceuticals Co Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
AU2021278303A1 (en) 2020-05-29 2023-02-09 Sumitomo Pharma Switzerland Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
FI3518933T4 (fi) 2025-05-14
CN110312512A (zh) 2019-10-08
AU2022241582B2 (en) 2024-06-13
ES2912929T5 (en) 2025-05-09
ES3018413T3 (es) 2025-05-16
PL3518933T5 (pl) 2025-05-05
RS63300B2 (sr) 2025-05-30
DK3518933T3 (da) 2022-05-30
EP3518933A2 (en) 2019-08-07
JP2019529575A (ja) 2019-10-17
HUE059101T2 (hu) 2022-10-28
NZ752916A (en) 2022-09-30
CA3038879A1 (en) 2018-04-05
US20220370462A1 (en) 2022-11-24
EP3518933B1 (en) 2022-03-16
AU2017336363B2 (en) 2022-08-04
SI3518933T1 (sl) 2022-06-30
US20240165118A1 (en) 2024-05-23
BR112019006227A2 (pt) 2019-06-18
IL300580B1 (en) 2025-07-01
US20190262346A1 (en) 2019-08-29
CN110312512B (zh) 2023-05-09
PL4094766T3 (pl) 2025-07-28
MX2019003726A (es) 2019-09-26
AU2022241582A1 (en) 2022-10-27
HRP20220708T1 (hr) 2022-07-22
IL265700B2 (en) 2023-07-01
HUE072130T2 (hu) 2025-10-28
RS63300B1 (sr) 2022-07-29
SI3518933T2 (sl) 2025-05-30
IL265700B1 (en) 2023-03-01
MD3518933T2 (ro) 2022-07-31
AU2017336363A1 (en) 2019-05-16
SMT202200254T1 (it) 2022-07-21
EP4094766A1 (en) 2022-11-30
EP3518933B2 (en) 2025-02-26
IL300580B2 (en) 2025-11-01
PL3518933T3 (pl) 2022-06-20
JP7043503B2 (ja) 2022-03-29
US11957684B2 (en) 2024-04-16
US11793812B2 (en) 2023-10-24
AU2022241582C1 (en) 2024-11-28
US20210401841A1 (en) 2021-12-30
IL265700A (en) 2019-05-30
CY1125254T1 (el) 2024-02-16
EP4094766B1 (en) 2025-04-02
PT3518933T (pt) 2022-05-10
WO2018060501A3 (en) 2018-05-11
LT3518933T (lt) 2022-06-10
US11033551B2 (en) 2021-06-15
IL300580A (en) 2023-04-01
HRP20220708T4 (hr) 2025-04-25
ES2912929T3 (es) 2022-05-30
WO2018060501A2 (en) 2018-04-05
MD3518933T4 (ro) 2025-10-31

Similar Documents

Publication Publication Date Title
DK3518933T4 (da) Fremgangsmåder til behandling af uterusfibromer og endometriose
DK3537765T3 (da) Fremgangsmåde og indretning til omskiftning
DK3259386T3 (da) Systemer og fremgangsmåder til udførelse af immunoassays
DK3183774T3 (da) Indretning og fremgangsmåde til ledning af elektromagnetiske bølger
DK3245225T3 (da) Sammensætninger og fremgangsmåder til behandling og detektering af cancere
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3516160T3 (da) Brøndanordning og tilhørende fremgangsmåder
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3285544T3 (da) Fremgangsmåde og indretning til behandling af indretning-til-indretning-synkroniseringssekvens
DK3519572T3 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3368663T3 (da) Virusfri cellelinjer og fremgangsmåder til opnåelse deraf
DK3230917T3 (da) System og fremgangsmåde til aktivering af sikker autentificering
DK3264799T3 (da) Fremgangsmåde og høreanordning til forbedret adskillelse af mållyde
DK3342571T3 (da) Blandeindretning og blandefremgangsmåde
DK3717851T3 (da) Fremgangsmåde og anordning til tørring af plader
DK3441381T3 (da) Fremgangsmåde til fremstilling af methanol og indretning til fremstilling af methanol
DK3254093T3 (da) Fremgangsmåde og anordning til bestemmelse af vandindhold
DK3387855T3 (da) Fremgangsmåder og arrangementer til at autentificere en kommunikationsindretning
DK3367852T3 (da) Indretning og fremgangsmåde til behandling af levnedsmidler
DK3821770T3 (da) Anordning og fremgangsmåde til opskumning af fluid
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3472338T3 (da) Midler og fremgangsmåder til at modifikation af flere alleler
DK3201624T3 (da) Indretning til detektion af hæmolyse, system og fremgangsmåde
DK3212659T3 (da) Midler og fremgangsmåder til stedspecifik funktionalisering af polypeptider